<DOC>
	<DOCNO>NCT02146625</DOCNO>
	<brief_summary>The objective study : - To evaluate safety tolerability CJ-40002 single SC injection healthy male volunteer . - To evaluate PK CJ-40002 single SC injection healthy male volunteer . - To evaluate PD CJ-40002 single SC injection healthy male volunteer . - To evaluate ADA CJ-40002 single SC injection healthy male volunteer .</brief_summary>
	<brief_title>Safety , Tolerability , PK , PD , ADA Escalating Single Dose CJ-40002 Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteer age 19 45 year old ( inclusive ) Body mass index ( BMI ) range 18.5 25 kg/m2 weigh least 55 kg Subject voluntarily agree participate trial sign write informed consent form , listen purpose , method , effect clinical trial History clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , musculoskeletal cardiovascular disease condition History allergy sensitivity drug Subject follow clinically significant laboratory abnormality : AST ALT &gt; 1.25 x Upper Limit Normal ( ULN ) Total bilirubin &gt; 1.5 x Upper Limit Normal ( ULN ) CPK &gt; 1.5 x Upper Limit Normal ( ULN ) eGFR &lt; 60 mL/min/1.73 m2 Systolic blood pressure outside range 90 150 mmHg diastolic blood pressure outside range 50 100 mmHg History drug abuse History caffeine , alcohol , smoke abuse Participation clinical investigation within 60days prior study medication dose Subjects whole blood donation within 60days , component blood donation within 30days prior study medication dose Positive test result HBs Ab , HCV Ab , HIV test Subjects consider unsuitable base medical judgement investigator</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>